Bladder Cancer
August 2017 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Bladder Cancer abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Bladder Cancer. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Bladder Cancer. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Bladder Cancer every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Preoperative High Neutrophil-to-Lymphocyte Ratio Is Associated with High-grade Bladder Cancer.
Authors:Tang X, Wang S, An C, DU P, Yang Y
Institution:Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China.; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China
Journal:Anticancer Res. 2017 Aug;37(8):4659-4663.

2:Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.
Authors:Phillips RM, Hendriks HR, Sweeney JB, Reddy G, Peters GJ
Institution:a Department of Pharmacy , University of Huddersfield , Huddersfield , UK. Netherlands.
Journal:Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):783-791. doi: 10.1080/17425255.2017.1341490. Epub 2017 Jul 3.

3:Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
Authors:Hafeez S, McDonald F, Lalondrelle S, McNair H, Warren-Oseni K, Jones K, Harris V, Taylor H, Khoo V, Thomas K, Hansen V, Dearnaley D, Horwich A, Huddart R
Institution:The Institute of Cancer Research, London; The Royal Marsden NHS Foundation Trust, Sutton, Surrey. Electronic address:; The Royal Marsden NHS Foundation Trust, London.
Journal:Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122. doi: 10.1016/j.ijrobp.2017.01.239. Epub 2017 Feb 9.

4:Emerging drugs for urothelial (bladder) cancer.
Authors:Cumberbatch K, He T, Thorogood Z, Gartrell BA
Institution:a Department of Medical Oncology , Montefiore Hospital and Medical Center , Bronx , NY , USA. , NY , USA. , NY , USA. , NY , USA.
Journal:Expert Opin Emerg Drugs. 2017 Jun;22(2):149-164. doi: 10.1080/14728214.2017.1336536. Epub 2017 Jun 12.

5:Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Authors:Farina MS, Lundgren KT, Bellmunt J
Institution:Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA. USA. USA. 08003, Barcelona, Spain.
Journal:Drugs. 2017 Jul;77(10):1077-1089. doi: 10.1007/s40265-017-0748-7.

6:A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
Authors:Sun F, Zhao R, Zhu Y, Cui D, Wang X, Han B, Liang S, Liu H, Sun X, Zhao F, Xu D, Xia S
Institution:Shanghai General Hospital, Shanghai, China.
Journal:Cancer Chemother Pharmacol. 2017 Jun;79(6):1099-1107. doi: 10.1007/s00280-017-3305-x. Epub 2017 Apr 18.

7:Tackling non-muscle invasive bladder cancer in the clinic.
Authors:Woldu SL, Sanli O, Lotan Y
Institution:a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA. Dallas , TX , USA. Istanbul , Turkey. Dallas , TX , USA.
Journal:Expert Rev Anticancer Ther. 2017 May;17(5):467-480. doi: 10.1080/14737140.2017.1313119. Epub 2017 Apr 11.

8:Management of Voiding Dysfunction After Female Neobladder Creation.
Authors:Hoy NY, Cohn JA, Kowalik CG, Kaufman MR, Stuart Reynolds W, Dmochowski RR
Institution:Division of Urology, University of Alberta, Edmonton, AB, Canada.; Department of Urologic Surgery, Vanderbilt University Medical Center, 1302A Medical Center North, Nashville, TN, 37232, USA.
Journal:Curr Urol Rep. 2017 May;18(5):33. doi: 10.1007/s11934-017-0682-y.

9:Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies.
Authors:Zainfeld D, Daneshmand S
Institution:USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA, 90089, USA. Angeles, CA, 90089, USA.
Journal:Curr Urol Rep. 2017 May;18(5):34. doi: 10.1007/s11934-017-0680-0.

10:Precision surgery and genitourinary cancers.
Authors:Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto JW, Hampton LJ, Lima E, Mirone V, Derweesh IH, Debruyne FMJ
Institution:Urology Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA. Electronic address: Electronic address: Heidelberg, Germany. Electronic address: address: Electronic address: University of Minho, and Department of CUF Urology, Braga, Portugal. Electronic address: address:
Journal:Eur J Surg Oncol. 2017 May;43(5):893-908. doi: 10.1016/j.ejso.2017.02.005. Epub 2017 Feb 20.

11:Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.
Authors:Fernandez MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM
Institution:Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Cancer Center, Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA.
Journal:BJU Int. 2017 May;119(5):684-691. doi: 10.1111/bju.13689. Epub 2016 Nov 11.

For a FREE PREVIEW of the Medifocus Guidebook on Bladder Cancer click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Bladder Cancer click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Bladder Cancer...
at a Special 20% Discount

Medifocus Guidebook on Bladder Cancer

Updated: June 20, 2017
167 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Bladder Cancer is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: October 25, 2017

What Our Customers Are Saying...

"My father, a veterinarian, was recently diagnosed with invasive bladder cancer. In wondering how best to support him, I decided to gift him a copy of the MediFocus Guidebook on Bladder Cancer. I knew it would appeal to his "scientific side". I wrote a loving and personal message in the Guide to remind him how much I loved him and then gave it to him. After reading the Guide, he took it to his Urologist and was able to generate excellent and candid questions about his condition."
Modesto, California

"This Medifocus Guidebook was significantly helpful at a time that we needed information quickly. We felt we gained information that offered us insight on what to ask our physician, as well as a preview of options on treatment and risk factors that he would probably discuss with us. Emotionally, it's a 'god-send' to look up and receive information immediately. Thanks."
Crestview, Florida

Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.